Delayed-Action Preparations
"Delayed-Action Preparations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Dosage forms of a drug that act over a period of time by controlled-release processes or technology.
| Descriptor ID |
D003692
|
| MeSH Number(s) |
D26.255.210 E02.319.300.253
|
| Concept/Terms |
Controlled-Release Preparations- Controlled-Release Preparations
- Controlled Release Preparations
- Controlled-Release Preparation
- Controlled-Release Formulations
- Controlled Release Formulations
- Controlled-Release Formulation
Sustained-Release Preparations- Sustained-Release Preparations
- Sustained-Release Preparation
- Extended Release Preparations
- Extended Release Preparation
- Slow Release Formulation
- Sustained Release Formulations
- Sustained Release Formulation
- Extended Release Formulations
- Extended Release Formulation
|
Below are MeSH descriptors whose meaning is more general than "Delayed-Action Preparations".
Below are MeSH descriptors whose meaning is more specific than "Delayed-Action Preparations".
This graph shows the total number of publications written about "Delayed-Action Preparations" by people in this website by year, and whether "Delayed-Action Preparations" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 3 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 4 | 4 |
| 2017 | 5 | 41 | 46 |
| 2018 | 11 | 42 | 53 |
| 2019 | 5 | 12 | 17 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Delayed-Action Preparations" by people in Profiles.
-
Cost-effectiveness of Treatments for Opioid Use Disorder. JAMA Psychiatry. 2021 07 01; 78(7):767-777.
-
Biomaterials and nanomaterials for sustained release vaccine delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 11; 13(6):e1735.
-
Ethyl cellulose coated sustained release aspirin spherules for treating COVID-19: DOE led rapid optimization using arbitrary interface; applicable for emergency situations. Int J Biol Macromol. 2021 Jul 01; 182:1769-1784.
-
Buprenorphine: extended-release formulations "a game changer"! Med J Aust. 2021 06; 214(11):534-534.e1.
-
Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro. Nanomedicine (Lond). 2021 06; 16(14):1187-1202.
-
Statement from the Japanese Respiratory Society: Working diagnosis and initial management of COPD during the COVID-19 pandemic. Respir Investig. 2021 Jul; 59(4):385-388.
-
Bupropion for postpartum smoking relapse: A remote protocol for a two-arm, double-blind, placebo-controlled randomized clinical trial. Contemp Clin Trials. 2021 06; 105:106352.
-
Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment. Int J Pharm. 2021 Mar 15; 597:120329.
-
More than just contraception: the impact of the levonorgestrel-releasing intrauterine system on public health over 30 years. BMJ Sex Reprod Health. 2021 07; 47(3):228-230.
-
Optimal Long-Acting Injectable Antipsychotic Management During COVID-19. J Clin Psychiatry. 2021 01 12; 82(1).